SCHEMBL7209293

SCHEMBL7209293

Nc1cc([N+](=O)[O-])c(Cl)c(Cl)c1Br

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 1/20 0.48
ALDH1A1 P00352 7/20 0.44
CYP3A4 P08684 4/20 0.44
TDP1 Q9NUW8 6/20 0.43
TSHR P16473 4/20 0.43
ALOX15 P16050 2/20 0.43
HPGD P15428 1/20 0.43
HIF1A Q16665 1/20 0.43
TXNRD1 Q16881 1/20 0.43
TXNRD3 Q86VQ6 1/20 0.43
TXNRD2 Q9NNW7 1/20 0.43
VCAM1 P19320 1/20 0.43
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 1/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 1/20 0.41
PDE7A Q13946 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11558066 0.82 GPR35 (0.59) GPR35ALDH1A1CYP3A4TDP1TSHR
SCHEMBL27880083 0.78 GPR35 (0.50) GPR35ALDH1A1CYP3A4TDP1TSHR
SCHEMBL6186321 0.76 ALDH1A1 (0.55) GPR35ALDH1A1CYP3A4TDP1TSHR
SCHEMBL6186665 0.76 ALDH1A1 (0.48) ALDH1A1CYP3A4TDP1TSHRHPGD
SCHEMBL20535866 0.74 ALDH1A1 (0.53) GPR35ALDH1A1CYP3A4TDP1TSHR
SCHEMBL8654568 0.74 GPR35 (0.71) GPR35ALDH1A1CYP3A4TDP1TSHR
SCHEMBL22637083 0.73 ALDH1A1 (0.49) ALDH1A1CYP3A4TDP1TSHRALOX15
SCHEMBL7209289 0.73 ALDH1A1 (0.47) GPR35ALDH1A1CYP3A4TDP1TSHR
SCHEMBL27916755 0.73 TDP1 (0.47) ALDH1A1CYP3A4TDP1TSHRALOX15
SCHEMBL2837407 0.73 ALDH1A1 (0.55) GPR35ALDH1A1CYP3A4TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6617315-B1 Sugar-substituted benzimidazole derivatives are used for the treatment or prophylaxis of restenosis, particularly following angioplasty CHAMBERLAIN STANLEY DAWES (US) 2003-09-09 US disclosed